HEALTHCARE

December 9, 2019

WHO Provides Healthcare Services at 25 Medical Centres

Tripoli, 8 December 2019(Lana) Emergency Medical Caravans of the World Health Organisation have offered life-saving healthcare support to patients at 25 medical centres in Libya.

'Thanks"...

Read More >>

December 9, 2019

Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis

Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis.

Prurigo"...

Read More >>

December 7, 2019

CFAO Embarks on HIV/AIDS Awareness Campaign

CFAO, a leader in specialised distribution of Mobility, Healthcare, Consumer goods, Technology and Energy with over 117 years of business existence in Nigeria, commemorated 2019 World Aids Day with a 7-kilometers walkathon to sensitise the public on HIV/AIDS within Victoria Island, Lagos.

"...

Read More >>

December 5, 2019

UAE Ministry of Health Collaborates with Vocera to Improve Care Team Communication and Optimise Patient Safety

Vocera Communications, Inc. (NYSE:VCRA), a recognised leader in clinical communication and workflow solutions, today announced that the Ministry of Health and Prevention of the United Arab Emirates plans to standardise care team communication using Vocera technology. An expected enterprise-wide deployment of the Vocera smartphone app and the new Vocera Smartbadge is part of a strategic alignment aimed at improving care team collaboration, optimising operational efficiency, and elevating patient care and safety. “Our partnership with Vocera and the implementation of the company’s unique solutions represents a breakthrough in our digital......

Read More >>

December 3, 2019

Gen Re and PAI Health Take Strategic Partnership to Next Level

Decades of evidence have proven cardiorespiratory fitness to be a leading predictor of longevity and future health. Yet it is one that has been largely overlooked within insurance customer health profiles. With the signing of the exclusive agreement between leading global reinsurer, Gen"...

Read More >>

December 1, 2019

Libya to pay part of debts to Italian company executing Tripoli University Hospital maintenance

An agreement has been reached between Libya and Italy, represented in the Under-Secretary of the Libyan Ministry of Health, Mohamed Haitham and the Italian Ambassador to Libya, Giuseppe Grimaldi, to pay part of the dues of the Italian company executing the infrastructure maintenance project"...

Read More >>

December 1, 2019

Makita Pink creates awareness on breast cancer

Every year in October, the colour pink is prominently showcased by thousands of organizations everywhere. October has been designated as the Pink Month in a global effort to raise awareness on Breast Cancer.

The"...

Read More >>

November 27, 2019

WHO provides anti-Leishmania medicines to Libya

TRIPOLI, Nov. 26 (Xinhua) -- The World Health Organization (WHO) on Tuesday said it has provided Libya with anti-Leishmania medicines.

'Recently, WHO in cooperation with NCDC (National Center for Disease Control)"...

Read More >>

November 27, 2019

GN CORPORATION: Vision Restored with Corneal Cell Transplant Using a Nano Sheet Technique; Japanese Firm Granted Patent in India

A novel cell transplantation method to treat corneal endothelial diseases such as bullous keratopathy using a nano-composite gel sheet developed by Japanese scientists was granted Indian patent to GN Corporation (GNC), Japan. This method was earlier granted a Japanese patent, in which one"...

Read More >>

November 27, 2019

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor. Results show after more than two years of follow-up, ALUNBRIG reduced the risk of disease progression or death by 76% (hazard ratio [HR] = 0.24, 95% CI: 0.12–0.45) as assessed by investigators in newly diagnosed patients whose disease had spread to the brain at time of enrollment. ALUNBRIG also demonstrated a 57% (HR = 0.43, 95% CI:......

Read More >>

Found articles: - Pages